The IPO Buzz: Cancer Biotech Bicara Therapeutics (BCAX Proposed) Sets Terms & Launches $200 Million IPO
Cancer biotech Bicara Therapeutics (BCAX Proposed) disclosed the terms for its $200 million IPO early today – Friday, Sept. 6, 2024 – and launched the deal for a NASDAQ debut next week. The biotech, which is targeting head and neck squamous cell cancer, is offering 11.765 million shares at a price range of $16.00 to […]
September 6, 2024 Read More